Cargando…

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for relapsed/refractory B cell precursor acute lymphoblasti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viardot, Andreas, Locatelli, Franco, Stieglmaier, Julia, Zaman, Faraz, Jabbour, Elias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481145/ https://www.ncbi.nlm.nih.gov/pubmed/32856140 http://dx.doi.org/10.1007/s00277-020-04221-0

Ejemplares similares

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Concepts and Applications of Information Theory to Immuno-Oncology
por: Karolak, Aleksandra, et al.
Publicado: (2021)

Immuno-oncology-microbiome axis of gastrointestinal malignancy
por: Lin, Quan, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Immuno-oncology for B-cell lymphomas
por: Choi, Yoon Seok
Publicado: (2021)

Single-Cell Analysis in Immuno-Oncology
por: Christodoulou, Maria-Ioanna, et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Rodak, Aleksandra, et al.
Publicado: (2021)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Novel strategies for immuno-oncology breakthroughs with cell therapy
por: Liu, Hongtao, et al.
Publicado: (2021)

Inducing immunogenic cell death in immuno-oncological therapies
por: Ti, Dongdong, et al.
Publicado: (2022)

The use of single-cell multi-omics in immuno-oncology
por: Ma, Anjun, et al.
Publicado: (2022)

Tackling key immunological and immuno-dermatological pathways and their link to treatment options
por: Boda, Daniel
Publicado: (2020)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
por: Sánchez, Javier, et al.
Publicado: (2023)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
por: Morcos, Peter N., et al.
Publicado: (2020)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_obpvtf89311sld8vu1tju4ohnb